Back to Search
Start Over
O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N 6 -methyladenosine-dependent manner.
- Source :
-
Signal transduction and targeted therapy [Signal Transduct Target Ther] 2023 Feb 10; Vol. 8 (1), pp. 63. Date of Electronic Publication: 2023 Feb 10. - Publication Year :
- 2023
-
Abstract
- Hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC), but its pathogenic mechanism remains to be explored. The RNA N <superscript>6</superscript> -methyladenosine (m <superscript>6</superscript> A) reader, YTH (YT521-B homology) domain 2 (YTHDF2), plays a critical role in the HCC progression. However, the function and regulatory mechanisms of YTHDF2 in HBV-related HCC remain largely elusive. Here, we discovered that YTHDF2 O-GlcNAcylation was markedly increased upon HBV infection. O-GlcNAc transferase (OGT)-mediated O-GlcNAcylation of YTHDF2 on serine 263 enhanced its protein stability and oncogenic activity by inhibiting its ubiquitination. Mechanistically, YTHDF2 stabilized minichromosome maintenance protein 2 (MCM2) and MCM5 transcripts in an m <superscript>6</superscript> A-dependent manner, thus promoting cell cycle progression and HBV-related HCC tumorigenesis. Moreover, targeting YTHDF2 O-GlcNAcylation by the OGT inhibitor OSMI-1 significantly suppressed HCC progression. Taken together, our findings reveal a new regulatory mechanism for YTHDF2 and highlight an essential role of YTHDF2 O-GlcNAcylation in RNA m <superscript>6</superscript> A methylation and HCC progression. Further description of the molecular pathway has the potential to yield therapeutic targets for suppression of HCC progression due to HBV infection.<br /> (© 2023. The Author(s).)
Details
- Language :
- English
- ISSN :
- 2059-3635
- Volume :
- 8
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Signal transduction and targeted therapy
- Publication Type :
- Academic Journal
- Accession number :
- 36765030
- Full Text :
- https://doi.org/10.1038/s41392-023-01316-8